Covid-19: Doctors in Norway told to assess severely frail patients for vaccination
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n167 (Published 19 January 2021) Cite this as: BMJ 2021;372:n167Read our latest coverage of the coronavirus outbreak

All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Dear Editor
On December 1, 2020 I received an email from the distinguished author of an American textbook of pediatric infectious diseases. He was severely critical of my November 13, 2020 rapid response (https://www.bmj.com/content/371/bmj.m4374/rr-4), particularly my calculation that 256 individuals would have to receive Pfizer’s vaccine to prevent a single Covid-19 illness. In the language of the clinical epidemiologist, 256 is the Number Needed To Vaccinate (NNTV). It is the vaccine equivalent of the Number Needed To Treat (NNTT), which is used to measure the real-world benefit of drugs and procedures for individuals. (Sackett et al, Clinical Epidemiology, 1991) Application of the concept to vaccines is controversial. Most public health authorities emphasize the population benefit of vaccines and herd immunity over individual benefit, and it is no surprise that manufacturers support this emphasis because it fosters greater vaccine uptake. Others believe that NNTV is a useful measure of the impact and cost-effectiveness of immunization programs. (Hashim et al, Vaccine 2015;33:753)
Fresh questions about safety and effectiveness have been aroused by a report of 33 deaths in elderly Norwegians shortly after their first dose of Pfizer’s Covid-19 vaccine. (Torjesen, BMJ 2021;372:n167, Jan 19) Our knowledge is limited, but NNTV is a straightforward way to quantitate individual benefit. The latest published information indicates that the absolute risk reduction (ARR) by the vaccine for any Covid-19 illness is 0.0046 for individuals 65 and older. (Calculated from Table 3 in Polack et al, NEJM 2020;383:2603, Dec 31) The NNTV is 1/0.0046=217. This means that 216 old people will derive no benefit but will be subject to adverse effects….There are at least two qualifications for this calculation: first, the NNTV for severe illnesses and deaths is likely to be much higher; second, NNTV is likely to change with time as the calculated ARR and vaccine effectiveness change with time.
I hope the foregoing will not be misquoted or used on social media (which I rigidly avoid) in a misleading way. Meanwhile, we still have a lot to learn about Covid-19 vaccines, something we should know from our experience with influenza vaccines (https://www.bmj.com/content/371/bmj.m4037/rr-3).
ALLAN S. CUNNINGHAM 28 January 2021
Competing interests: No competing interests
Dear Editor
The article makes the point that "for most elderly frail people any side effects of the vaccine will be outweighed by a reduced risk of a severe covid-19 disease"
I just wonder how that claim can be true when Peter Doshi, associate editor at the BMJ and assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy tells us quite clearly that none of the vaccine trials were designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths.
https://www.bmj.com/content/371/bmj.m4037
That in turn leads us to the thorny issue of informed consent. How can a patient give informed consent to a vaccine when they have not been told that the drug they are having injected has not been trialed to see if it does reduce serious outcomes? This is then compounded when the second dose is not given within the time scale specified by the manufacturers and the patient is not informed of this fact.
As eminent doctors and academics have pointed out "The current UK strategy with the Pfizer mRNA vaccine is, in our view, a non-randomised, uncontrolled population experimental study without pilot data. "
https://blogs.bmj.com/bmj/2021/01/20/revisiting-the-uks-strategy-for-del...
As advocates for their patients should doctors not be advising them of these points and then discussing and assessing whether there may or may not be a benefit in vaccination for that individual?
Competing interests: No competing interests
Dear Editor,
Reports from Norway do carry a distinct message. Though the elderly (particularly with comorbid conditions) have borne the brunt in the reported Covid mortality, it may be erroneous to club the 'elderly' togeter into a homogeneous entity.
In fact, the concepts of 'prefrailty', 'Frailty Syndrome' tend to be under recognised or hardly taken into account in clinical contexts. Any minor clinical condition or external administration can tip the scales against the frail with a highly compromised 'internal milieu'. The vaccine programme and schedules are operational on a global scale, and let vaccine administration, without adequate prior clinical assessment in the elderly, not turn into a repetitive adversity.
Dr Murar E Yeolekar, Mumbai.
Competing interests: No competing interests
Dear Editor
Well done to the BMJ on raising this issue. It is depressing how many doctors just see this as 'click bait' news.
I have kept an eye on the BBC news and there is no mention of the Norway experience and the advice by a neighboring medical body about actively considering the pros and cons of vaccination in the frail elderly. The silence of state media speaks volumes to how government may be approaching this issue. It will be interesting to see how many yellow cards were issued - the website is requesting such fine details such as batch numbers, which suggest the aim is to pick up very acute reactions.
Do we know if patients presenting to hospital are proactively asked if they have had the vaccine? If this is not done how will delayed presentations (even deaths) be picked up? My concern is the system has been set up (willfully or naively) to maintain a vaccination program at any cost and thus we have a feedback system that will equate lack of evidence of harm as evidence of lack of harm.
Competing interests: No competing interests
Dear Editor
The deaths of frail elderly after vaccination , and subsequent guidance to Norwegian doctors to perform an assessment instead of issuing universal guidance on vaccinations for their patients, has reanimated an old medical concept: fitness for vaccination.
Vaccination used to be an individual decision, made jointly by patient and doctor, that the benefits of a vaccine for that patient exceeded the expected harms. Patients paid small sums to be vaccinated.
Payment systems changed, and the government or insurance companies took over paying for vaccinations. Then the Affordable Care Act in the US waived all copayments, allowing pharmacies and grocery stores to advertise "free" vaccinations while you shop. Pediatricians were given bonuses if they reached assigned target levels of "fully vaccinated" children, which could amount to tens of thousands of dollars.
Vaccine mandates were brought in, and became tighter over the ensuing years. Children who are not fully vaccinated cannot attend school in certain states, regardless of their religious or philosophical orientation.
To make the mandates work, the concept of "fitness for vaccination" was undermined, then deeply buried. All vaccines became "safe and effective."
It is a tragedy that deaths and anaphylac events have occurred following Covid vaccinations. But maybe some good will come of it, by focusing awareness on the fact that vaccines are drugs, whose use is never absolutely risk free. Let us hope that the idea of establishing fitness for vaccination has been permanently disinterred.
Competing interests: No competing interests
Dear Editor
Can we assume that the NHS is linking covid vaccination and subsequent events such as subsequent proven covid infections or other serious incidents as a live activity through the GP data bases on a daily basis and will report any worries, such as we are hearing from Norway?
With now 4 million vaccinations given this data must be out there, and no news is good news - or so I hope and share when asking for consent to jab.
Competing interests: I am involved with giving covid vaccines
Re: Covid-19: Doctors in Norway told to assess severely frail patients for vaccination
Dear Editor,
On January 6, 2021, CDC posted a report entitled "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine" in Morbidity and Mortality Weekly Report.
During 14 to 23 December 2020, CDC collected 21 cases anaphylaxis after administration 1,893,360 first doses of the vaccine in the United States. The allergic reaction rate is 11.3 per million doses. No deaths from anaphylaxis were reported. Among these 21 patients, 7 (33%) had experienced anaphylaxis previously. Therefore 14 cases (67%) had their first episodes of anaphylaxis.
Evidently, anaphylaxis still remains rare after vaccination. In this context, the benefits of COVID-19 vaccination outweighed the risks.
Reference:
https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7002e1-H.pdf?ACSTrackingID...
Competing interests: No competing interests